- Home
- RIGL vs MDXG Comparison
RIGL vs MDXG Comparison
Compare RIGL & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RIGL | MDXG |
|---|---|---|
| Founded | 1996 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 564.7M | 530.2M |
| IPO Year | 2000 | 2007 |
Fundamental Metrics
Financial Performance| Metric | RIGL | MDXG |
|---|---|---|
| Price | $32.83 | $3.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $45.67 | $9.00 |
| AVG Volume (30 Days) | 279.0K | ★ 1.1M |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1867.68 | 14.29 |
| EPS | ★ 0.44 | N/A |
| Revenue | $294,282,000.00 | ★ $418,630,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.75 | $13.02 |
| P/E Ratio | $76.05 | ★ N/A |
| Revenue Growth | ★ 64.15 | 19.99 |
| 52 Week Low | $18.14 | $3.03 |
| 52 Week High | $52.24 | $7.99 |
Technical Indicators
Market Signals| Indicator | RIGL | MDXG |
|---|---|---|
| Relative Strength Index (RSI) | 61.89 | 51.77 |
| Support Level | $28.14 | $3.47 |
| Resistance Level | $33.09 | $3.84 |
| Average True Range (ATR) | 1.40 | 0.13 |
| MACD | 0.29 | 0.00 |
| Stochastic Oscillator | 73.86 | 52.50 |
Price Performance
Historical ComparisonAbout RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
About MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.